Colon

ALLIANCE A212102 **AT MBMC ONLY** **White female participants under (<) age 60 without a cancer diagnosis will temporarily be suspended on 12/1/22 3:30 cst**

Blinded Reference Set For Multicancer Early Detection Blood Tests

---

URCC 19075 **MBMC ONLY** (Temporarily Closed to Enrollment)

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)

---

A222004 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

---

URCC-21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

---

NCI 10323

Cancer Moonshot Biobank Research Protocol

---

NSABP C-14 / CORRECT-MRD II

Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease

---

A221805

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

---

NRG-GI005

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

---

WF 1806

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

---